Analysis of Different Clinical Scenarios using Daratumumab | Rafael Fonseca, MD | Ash 2021

Next steps in myeloma: quadruplets, immunotherapy, and replacing transplantПодробнее

Optimizing treatment sequencing in multiple myeloma: daratumumab upfront versus subsequent linesПодробнее

Rafael Fonseca, MD, discusses frontline multiple myeloma treatment patternsПодробнее

Myeloma highlights at ASH 2021Подробнее

Dr. Fonseca on FDA Approval of Daratumumab Triplets in Multiple MyelomaПодробнее

Seeking specialty care for multiple myeloma Rafael Fonseca, M.D., Mayo ClinicПодробнее

What is Multiple Myeloma? | Dr. Rafael Fonseca, M.D. | The Patient StoryПодробнее

The role of MRD Testing in Myeloma | Rafael Fonseca, MD | ASH 2021Подробнее

MRD Tests and Applications — Rafael Fonseca, MD | MCRT Webcast August 29 (2/4)Подробнее

Practical Information on Immunotherapy UseПодробнее

Multiple Myeloma: Looking Ahead | Dr. Rafael Fonseca (5/5) | The Patient StoryПодробнее

MCRT Phoenix 2017: Determining the Right Therapy Strategy by Rafael Fonseca, MDПодробнее

Measuring treatment response rates in multiple myelomaПодробнее

Myeloma Test Results and Factors That Impact Treatment DecisionsПодробнее

Myeloma Crowd Radio: HealthTree With Rafael Fonseca, MD, Mayo ClinicПодробнее

Metabolomics | Rafael Fonseca, MD | IMS 2022Подробнее

Key Take Aways from IMS 2023 | Rafael Fonseca, MD | IMS 2023Подробнее

Rafael Fonseca, MD, discusses maintenance regimens for multiple myelomaПодробнее